Cargando…
NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial)
BACKGROUND: Preoperative radiochemotherapy (RCT) is recommended in France prior to total mesorectal excision in patients with mid or low locally advanced rectal cancer (LARC) (cT3/T4 and/or N+) because it has been shown to improve local control. Preoperative RCT has also disadvantages including the...
Autores principales: | Brouquet, Antoine, Bachet, Jean-Baptiste, Huguet, Florence, Karoui, Mehdi, Artru, Pascal, Sabbagh, Charles, Lefèvre, Jérémie H., Vernerey, Dewi, Mariette, Christophe, Vicaut, Eric, Benoist, Stephane |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7257230/ https://www.ncbi.nlm.nih.gov/pubmed/32471382 http://dx.doi.org/10.1186/s12885-020-06968-1 |
Ejemplares similares
-
A multicentric randomized controlled trial on the impact of lengthening the interval between neoadjuvant radiochemotherapy and surgery on complete pathological response in rectal cancer (GRECCAR-6 trial): rationale and design
por: Lefevre, Jérémie H, et al.
Publicado: (2013) -
Are colorectal cancer patients at risk for COVID-19 infection during the postoperative period? The Covid-GRECCAR study
por: Tuech, Jean-Jacques, et al.
Publicado: (2021) -
A multicentre randomised controlled trial to evaluate the efficacy, morbidity and functional outcome of endoscopic transanal proctectomy versus laparoscopic proctectomy for low-lying rectal cancer (ETAP-GRECCAR 11 TRIAL): rationale and design
por: Lelong, Bernard, et al.
Publicado: (2017) -
GRECCAR 8: impact on survival of the primary tumor resection in rectal cancer with unresectable synchronous metastasis: a randomized multicentre study
por: Cotte, Eddy, et al.
Publicado: (2015) -
Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)
por: Schwarz, Lilian, et al.
Publicado: (2018)